» Articles » PMID: 23555976

Mesenchymal Stem Cells Engineered to Inhibit Complement-mediated Damage

Overview
Journal PLoS One
Date 2013 Apr 5
PMID 23555976
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSC) preferentially migrate to damaged tissues and, due to their immunomodulatory and trophic properties, contribute to tissue repair. Although MSC express molecules, such as membrane cofactor protein (CD46), complement decay-accelerating factor (CD55), and protectin (CD59), which confer protection from complement-mediated lysis, MSC are recruited and activated by anaphylatoxins after transplantation, potentially causing MSC death and limiting therapeutic benefit. We have previously demonstrated that transduction of MSC with a retrovirus encoding HCMV-US proteins resulted in higher levels of MSC engraftment due to decreased HLA-I expression. Here, we investigate whether engineering MSC to express US2 (MSC-US2), US3 (MSC-US3), US6 (MSC-US6), or US11 (MSC-US11) HCMV proteins can alter complement recognition, thereby better protecting MSC from complement attack and lysis. HCMV-US proteins increased MSC CD59 expression at different levels as determined by flow cytometric evaluation of the median fluorescence intensity ratio (MFI). A significant increase in CD59 expression was seen in MSC-US2, MSC-US3, and MSC-US6, but not in MSC-US11. Only MSC-US2 displayed increased expression of CD46, while US2 and US3 proteins were both able to augment the percentage of MSC expressing this molecule. Regardless of the HCMV protein expressed, none changed CD55 MFI; however, expression of US6, US11, and US2 each increased the percentage of MSC that were positive for this molecule. Because US2 protein was the most efficient in up-regulating all three complement regulatory proteins, we used a functional complement-mediated cytotoxicity assay to investigate whether MSC-US2 were protected from complement-mediated lysis. We demonstrated that over-expression of the US2 protein reduced complement lysis by 59.10±12.89% when compared to untransduced MSC. This is the first report, to our knowledge, describing a role of HCMV-US proteins in complement evasion, and our data shows that over-expression of US2 protein on MSC could serve as a strategy to protect these cells from complement lysis.

Citing Articles

Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights.

Hoseinzadeh A, Esmaeili S, Sahebi R, Melak A, Mahmoudi M, Hasannia M Stem Cell Res Ther. 2025; 16(1):33.

PMID: 39901306 PMC: 11792531. DOI: 10.1186/s13287-025-04158-z.


Human Liver MSCs Retain Their Basic Cellular Properties in Chronically Inflamed Liver Tissue.

Kim Y, Lupatov A, Burunova V, Bagmet N, Chardarov N, Malov S Int J Mol Sci. 2025; 25(24.

PMID: 39769138 PMC: 11676302. DOI: 10.3390/ijms252413374.


Precision Nanomedicine with Bio-Inspired Nanosystems: Recent Trends and Challenges in Mesenchymal Stem Cells Membrane-Coated Bioengineered Nanocarriers in Targeted Nanotherapeutics.

Baig M, Ahmad A, Pathan R, Mishra R J Xenobiot. 2024; 14(3):827-872.

PMID: 39051343 PMC: 11270309. DOI: 10.3390/jox14030047.


Adipose tissue-derived human mesenchymal stromal cells can better suppress complement lysis, engraft and inhibit acute graft-versus-host disease in mice.

Wu S, Zhu M, Chik S, Kwok M, Javed A, Law L Stem Cell Res Ther. 2023; 14(1):167.

PMID: 37357314 PMC: 10291819. DOI: 10.1186/s13287-023-03380-x.


Mesenchymal progenitor cells from non-inflamed versus inflamed synovium post-ACL injury present with distinct phenotypes and cartilage regeneration capacity.

Krawetz R, Larijani L, Corpuz J, Ninkovic N, Das N, Olsen A Stem Cell Res Ther. 2023; 14(1):168.

PMID: 37357305 PMC: 10291760. DOI: 10.1186/s13287-023-03396-3.


References
1.
Diaz T, Pertega S, Ortega D, Lopez E, Centeno A, Manez R . FDA/PI flow cytometry assay of complement-mediated cytotoxicity of antibodies generated during xenotransplantation. Cytometry A. 2004; 62(1):54-60. DOI: 10.1002/cyto.a.20076. View

2.
Meyers J, Flournoy N, Thomas E . Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986; 153(3):478-88. DOI: 10.1093/infdis/153.3.478. View

3.
Jiang H, Wek S, McGrath B, Scheuner D, Kaufman R, Cavener D . Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol Cell Biol. 2003; 23(16):5651-63. PMC: 166326. DOI: 10.1128/MCB.23.16.5651-5663.2003. View

4.
Spiller O, Morgan B, Tufaro F, Devine D . Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur J Immunol. 1996; 26(7):1532-8. DOI: 10.1002/eji.1830260719. View

5.
Spear G, Lurain N, Parker C, Ghassemi M, Payne G, Saifuddin M . Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol. 1995; 155(9):4376-81. View